PLUS1
6.00
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
2.3501
High
19.10
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Edesa Biotech Inc | EDSA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 6.00 | 08:19:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.00 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 5.85 | 6.05 | 0.20 | - | - |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 10 | 148 | 205,263 | 2.3501 - 19.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:44:54 | 30 | $ 6.06 | USD |
Edesa Biotech Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 79.07M | 13.18M | 7.80M | $ 211.85k | $ - | -0.74 | -6.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 10.01k | 5.70% |
Edesa Biotech News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/26/2021 | 17:02 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 17:00 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 16:57 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 16:56 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 16:54 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 16:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/26/2021 | 16:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EDSA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.3844 | 7.22 | 5.41 | 6.27 | 563,008 | -0.3844 | -6.02% |
| 1 Month | 5.64 | 7.22 | 4.93 | 6.04 | 207,153 | 0.36 | 6.38% |
| 3 Months | 7.36 | 8.2139 | 4.41 | 6.02 | 287,998 | -1.36 | -18.48% |
| 6 Months | 5.96 | 9.0999 | 4.0548 | 6.42 | 401,811 | 0.04 | 0.67% |
| 1 Year | 2.53 | 19.10 | 2.3501 | 7.02 | 717,801 | 3.47 | 137.15% |
| 3 Years | 5.15 | 19.10 | 1.58 | 6.82 | 438,318 | 0.85 | 16.5% |
| 5 Years | 5.15 | 19.10 | 1.58 | 6.82 | 438,318 | 0.85 | 16.5% |
Edesa Biotech Description
| Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients. |
